Cargando…
Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
Hemophilia is a rare genetic bleeding disorder that, if not adequately controlled, is associated with life-threatening bleeding events and serious and costly complications, primarily from joint damage. The advent of effective clotting factor replacement therapy for patients with hemophilia is consid...
Autor principal: | Pipe, Steven |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726050/ https://www.ncbi.nlm.nih.gov/pubmed/19707401 |
Ejemplares similares
-
Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A
por: Rossbach, Hans-Christoph
Publicado: (2010) -
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
por: Shah, Anita, et al.
Publicado: (2016) -
Advancing personalized care in hemophilia A: ten years’ experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method
por: Berntorp, Erik, et al.
Publicado: (2014) -
Prevention and Management of Bleeding Episodes in Children with Hemophilia
por: Ljung, Rolf C. R.
Publicado: (2018) -
Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting
por: Chen, Rong, et al.
Publicado: (2022)